Capricor Therapeutics, Inc. News: Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
Capricor Therapeutics, Inc. News: Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
Capricor Therapeutics is a biotechnology company offering a new approach on drug development in Duchenne muscular dystrophy and beyond. We are patient-focused first, while advancing precision medicine.
We offer a multi-stage pipeline exploring allogeneic cardiosphere-derived cells (CDCs) and exosome science for novel therapeutic approaches to treat a broad range of serious diseases.
View Our PipelineCapricor’s science is focused on cell and exosome-based biology, offering multiple modalities allowing us to create a new class of therapeutic medicines for patients.
Explore Our ScienceSign up today and receive company updates to your inbox.